Article: Genetic Engineering News' Poll Indicates Blockbuster Drug Reign Unlikely to End Soon.

Business Editors

LARCHMONT, N.Y.--(BUSINESS WIRE)--April 30, 2004

Despite the increasing amount of R&D on personalized medicine, blockbuster drugs will remain the main goal for many pharmaceutical firms, according to a recent Genetic Engineering News (GEN) website poll (www.genengnews.com). Three-hundred-and-forty-four individuals answered the poll, the results of which appear on page 1 of the April 15 issue of GEN.

The readers responded to the question "Will pharmacogenomics eventually end the reign of blockbuster drugs?" The results: 196 (57%) said "no" and 148 (43%) replied "yes."

"While it is too early to tell to what degree ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!